Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 5/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2149027 | 0.83 | GNAO1 (0.39) | GNAO1GNAI3GNAI1ITGB3ITGA2B | |
| SCHEMBL13107222 | 0.83 | TSHR (0.46) | TSHRCYP1A2SMN1; SMN2 | |
| SCHEMBL14395367 | 0.82 | SMN1; SMN2 (0.48) | GNAO1GNAI3GNAI1TSHRTLR7 | |
| Hydrochloric Acid SCHEMBL28699778 | 0.82 | GNAO1 (0.41) | GNAO1GNAI3GNAI1TLR7ITGB3 | |
| SCHEMBL293828 | 0.81 | CYP1A2 (0.58) | GNAO1GNAI3GNAI1CYP1A2ITGB3 | |
| SCHEMBL13335378 | 0.80 | ITGB3 (0.52) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Piperazine SCHEMBL28236561 | 0.80 | TSHR (0.52) | GNAO1GNAI3GNAI1TSHRSMN1; SMN2 | |
| SCHEMBL20745114 | 0.80 | SLC6A4 (0.39) | GNAO1ITGB3ITGA2BSLC6A4 | |
| SCHEMBL7765919 | 0.79 | CYP1A2 (0.64) | TSHRCYP1A2SMN1; SMN2 | |
| SCHEMBL27756951 | 0.79 | GNAO1 (0.46) | GNAO1GNAI3GNAI1TSHRITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010045212-A2 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INCSTATUTS (US) | 2010-04-22 | — | — | WO | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-5925642-A | ANTITUMOR, ANTIMETASTASIS AGENTS; DRUG RESISTANCE MODULATORS; SYNERGISTIC MIXTURES WITH ANTIBIOTICS AND CYTOSTATIC AGENTS; SIDE EFFECT REDUCTION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-07-20 | — | — | US | disclosed |
| US-5668131-A | CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-09-16 | — | — | US | disclosed |
| US-3998827-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | NR0B2, NR0B1, ADORA2B | GNAO1 204/4885GNAI3 2151/4885GNAI1 2252/4885 |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | GNAO1 578/4885GNAI3 1400/4885GNAI1 1325/4885 |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | GNAO1 578/4885GNAI3 1400/4885GNAI1 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.